Geron Corp. Stock
Geron Corp. Stock
Geron Corp. dominated the market today, gaining €0.39 (11.110%).
With 10 Buy predictions and not the single Sell prediction the community is currently very high on Geron Corp..
With a target price of 4 € there is a slightly positive potential of 3.71% for Geron Corp. compared to the current price of 3.86 €.
So far the community has only identified positive things for Geron Corp. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Geron Corp. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Geron Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Geron Corp. | 11.110% | 2.018% | 15.924% | 64.100% | 79.776% | 183.040% | 114.554% |
| Ardelyx Inc. | -0.970% | -1.640% | -11.302% | 48.049% | 3.737% | -18.973% | - |
| Salarius Pharmaceuticals Inc. | -1.840% | 1.429% | 0.472% | -70.417% | -23.243% | -98.377% | -99.993% |
| Brainstorm Cell | -5.760% | -2.456% | -5.429% | -82.011% | 114.009% | -83.450% | - |
Comments
Geron Co. (NASDAQ: GERN) is now covered by analysts at TD Cowen. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
News
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron Inc. (NASDAQ: GERN) is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their
Geron (GERN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q4 2023 Earnings CallFeb 28, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Geron (GERN) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
Geron (NASDAQ: GERN)Q3 2023 Earnings CallNov 02, 2023, 9:00 a.m. ET
Operator
Source Fool.com